189 related articles for article (PubMed ID: 24710512)
21. STX140 is efficacious in vitro and in vivo in taxane-resistant breast carcinoma cells.
Newman SP; Foster PA; Stengel C; Day JM; Ho YT; Judde JG; Lassalle M; Prevost G; Leese MP; Potter BV; Reed MJ; Purohit A
Clin Cancer Res; 2008 Jan; 14(2):597-606. PubMed ID: 18223236
[TBL] [Abstract][Full Text] [Related]
22. Successful in vivo hyperthermal therapy toward breast cancer by Chinese medicine shikonin-loaded thermosensitive micelle.
Su Y; Huang N; Chen D; Zhang L; Dong X; Sun Y; Zhu X; Zhang F; Gao J; Wang Y; Fan K; Lo P; Li W; Ling C
Int J Nanomedicine; 2017; 12():4019-4035. PubMed ID: 28603416
[TBL] [Abstract][Full Text] [Related]
23. Shikonin induces apoptosis through reactive oxygen species/extracellular signal-regulated kinase pathway in osteosarcoma cells.
Chang IC; Huang YJ; Chiang TI; Yeh CW; Hsu LS
Biol Pharm Bull; 2010; 33(5):816-24. PubMed ID: 20460760
[TBL] [Abstract][Full Text] [Related]
24. Shikonin suppresses proliferation and induces cell cycle arrest through the inhibition of hypoxia-inducible factor-1α signaling.
Li MY; Mi C; Wang KS; Wang Z; Zuo HX; Piao LX; Xu GH; Li X; Ma J; Jin X
Chem Biol Interact; 2017 Aug; 274():58-67. PubMed ID: 28684144
[TBL] [Abstract][Full Text] [Related]
25. Shikonin, a Chinese plant-derived naphthoquinone, induces apoptosis in hepatocellular carcinoma cells through reactive oxygen species: A potential new treatment for hepatocellular carcinoma.
Gong K; Li W
Free Radic Biol Med; 2011 Dec; 51(12):2259-71. PubMed ID: 22011623
[TBL] [Abstract][Full Text] [Related]
26. Antitumor Effect of Shikonin, a PKM2 Inhibitor, in Cholangiocarcinoma Cell Lines.
Thonsri U; Seubwai W; Waraasawapati S; Wongkham S; Boonmars T; Cha'on U; Wongkham C
Anticancer Res; 2020 Sep; 40(9):5115-5124. PubMed ID: 32878800
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of estrogen signaling activates the NRF2 pathway in breast cancer.
Yao Y; Brodie AM; Davidson NE; Kensler TW; Zhou Q
Breast Cancer Res Treat; 2010 Nov; 124(2):585-91. PubMed ID: 20623181
[TBL] [Abstract][Full Text] [Related]
28. Synergistic therapy of breast cancer with Y-90-chimeric L6 and paclitaxel in the xenografted mouse model: development of a clinical protocol.
Denardo SJ; Richman CM; Kukis DL; Shen S; Lamborn KR; Miers LA; Kroger LA; Perez EA; Denardo GL
Anticancer Res; 1998; 18(6A):4011-8. PubMed ID: 9891439
[TBL] [Abstract][Full Text] [Related]
29. Tunicamycin potentiates paclitaxel-induced apoptosis through inhibition of PI3K/AKT and MAPK pathways in breast cancer.
Huang S; Wang D; Zhang S; Huang X; Wang D; Ijaz M; Shi Y
Cancer Chemother Pharmacol; 2017 Oct; 80(4):685-696. PubMed ID: 28779263
[TBL] [Abstract][Full Text] [Related]
30. Shikonin induces an anti‑tumor effect on murine mammary cancer via p38‑dependent apoptosis.
Xu J; Koizumi K; Liu M; Mizuno Y; Suzaki M; Iitsuka H; Inujima A; Fujimoto M; Shibahara N; Shimada Y
Oncol Rep; 2019 Mar; 41(3):2020-2026. PubMed ID: 30664166
[TBL] [Abstract][Full Text] [Related]
31. Function of Aurora kinase A in Taxol-resistant breast cancer and its correlation with P-gp.
Li Y; Tang K; Zhang H; Zhang Y; Zhou W; Chen X
Mol Med Rep; 2011; 4(4):739-46. PubMed ID: 21584498
[TBL] [Abstract][Full Text] [Related]
32. [Expression and significance of heparin binding-epidermal growth factor-like growth factor in paclitaxel-resistant ovarian cancer].
Tang X; Lu M; Li C; Deng S; Li M
Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):517-22. PubMed ID: 25327734
[TBL] [Abstract][Full Text] [Related]
33. ER-mediated anti-tumor effects of shikonin on breast cancer.
Yang Y; Gao W; Tao S; Wang Y; Niu J; Zhao P; Rao C; Yang L
Eur J Pharmacol; 2019 Nov; 863():172667. PubMed ID: 31545985
[TBL] [Abstract][Full Text] [Related]
34. Shikonin induces apoptosis of lung cancer cells via activation of FOXO3a/EGR1/SIRT1 signaling antagonized by p300.
Jeung YJ; Kim HG; Ahn J; Lee HJ; Lee SB; Won M; Jung CR; Im JY; Kim BK; Park SK; Son MJ; Chung KS
Biochim Biophys Acta; 2016 Nov; 1863(11):2584-2593. PubMed ID: 27452907
[TBL] [Abstract][Full Text] [Related]
35. The role of the polyamine catabolic enzymes SSAT and SMO in the synergistic effects of standard chemotherapeutic agents with a polyamine analogue in human breast cancer cell lines.
Pledgie-Tracy A; Billam M; Hacker A; Sobolewski MD; Woster PM; Zhang Z; Casero RA; Davidson NE
Cancer Chemother Pharmacol; 2010 May; 65(6):1067-81. PubMed ID: 19727732
[TBL] [Abstract][Full Text] [Related]
36. Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment.
Pasquier E; Ciccolini J; Carre M; Giacometti S; Fanciullino R; Pouchy C; Montero MP; Serdjebi C; Kavallaris M; André N
Oncotarget; 2011 Oct; 2(10):797-809. PubMed ID: 22006582
[TBL] [Abstract][Full Text] [Related]
37. Octreotide-Paclitaxel Conjugate Reverses Paclitaxel Resistance by p38 Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway in A2780/Taxol Human Ovarian Cancer Cells.
Fan LL; Chen X; Zhang XY; Li ZM; Fan XM; Shen Y
Med Sci Monit; 2020 Aug; 26():e922612. PubMed ID: 32829374
[TBL] [Abstract][Full Text] [Related]
38. Pharmacological properties and derivatives of shikonin-A review in recent years.
Guo C; He J; Song X; Tan L; Wang M; Jiang P; Li Y; Cao Z; Peng C
Pharmacol Res; 2019 Nov; 149():104463. PubMed ID: 31553936
[TBL] [Abstract][Full Text] [Related]
39. PKM2 Inhibitor Shikonin Overcomes the Cisplatin Resistance in Bladder Cancer by Inducing Necroptosis.
Wang Y; Hao F; Nan Y; Qu L; Na W; Jia C; Chen X
Int J Biol Sci; 2018; 14(13):1883-1891. PubMed ID: 30443191
[TBL] [Abstract][Full Text] [Related]
40. Shikonin inhibits triple-negative breast cancer-cell metastasis by reversing the epithelial-to-mesenchymal transition via glycogen synthase kinase 3β-regulated suppression of β-catenin signaling.
Chen Y; Chen ZY; Chen L; Zhang JY; Fu LY; Tao L; Zhang Y; Hu XX; Shen XC
Biochem Pharmacol; 2019 Aug; 166():33-45. PubMed ID: 31071331
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
